Hemostasis Today

May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Natasha Jolakoski on Rethinking Lead-in Strategies in VTE
Dec 13, 2025, 17:31

Natasha Jolakoski on Rethinking Lead-in Strategies in VTE

Natasha Jolakoski, PGY-2 Thrombosis and Hemostasis Resident at The University of New Mexico Hospital, shared on LinkedIn:

”I’m excited to share that our multicenter study, “Rethinking lead-in strategies: evaluation of full vs. reduced-dose factor Xa inhibitors in acute VTE,” has been published in the Journal of Thrombosis and Thrombolysis.

This study evaluated bleeding and thrombotic outcomes associated with reducing factor Xa inhibitor lead-in duration in patients who received prior parenteral anticoagulation, across 1,400+ patients with acute VTE.

We found that a reduced lead-in approach was not associated with higher rates of VTE recurrence or major bleeding.

I’d like to thank my preceptors, Stephanie Edwin and Christopher Giuliano , for their guidance and support throughout this project, as well as all the co-authors who made this collaboration possible.”

Read the full article here.

Article: Rethinking lead-in strategies: evaluation of full vs. reduced dose factor Xa inhibitors in acute VTE

Authors: Natasha Jolakoski, Sarah Grazia, Clare Brewster, Brehanna Edwards, Danielle Rosas, Diana Penev, Whitney Anderson, Stephanie B. Edwin, Shannon Carabetta, Bradley Haan, Thomas Breedan, Megan Laux, Kathaleen Watson, Andrew Harpenau, Rachel Bruns, Josephine Varda, Kathleen Koopman, Meagan Paylor, Christopher Guiliano

Natasha Jolakoski on Rethinking Lead-in Strategies in VTE

Stay updated on all scientific advances with Hemostasis Today.